Research programme: prodrug therapeutics - Ascendis Pharma

Drug Profile

Research programme: prodrug therapeutics - Ascendis Pharma

Alternative Names: Transcon CNP; TransCon Hydrogel GLP-1; TransCon Hydrogel insulin; TransCon Hydrogel paliperidone; TransCon Hydrogel pramipexole; TransCon PEG interferon α; Transcon PTH

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Ascendis Pharma
  • Class Benzothiazoles; Glucagon-like peptides; Insulins; Interferons; Isoxazoles; Polyethylene glycols
  • Mechanism of Action C-type natriuretic peptide modulators; Dopamine D2 receptor agonists; Dopamine D2 receptor antagonists; Dopamine D3 receptor agonists; Dopamine D4 receptor agonists; Glucagon like peptide 1 receptor agonists; Insulin receptor agonists; Interferon alpha stimulants; Parathyroid hormone receptor modulators; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Achondroplasia; CNS disorders; Diabetes mellitus; Hepatitis C; Hypoparathyroidism

Most Recent Events

  • 31 Aug 2016 Preclinical trials in Achondroplasia in Denmark (unspecified route)
  • 31 Aug 2016 Preclinical trials in Hypoparathyroidism in Denmark (unspecified route)
  • 31 Aug 2016 Ascendis announces intention to submit IND application to the US FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top